Bio-Rad Laboratories, Inc.BIO-B stock score: 63/100

$389.98 · +0.00% · Scored Nov 19, 2026

Technical
66
Fundamental
62
News
—

The reading

Bio-Rad Laboratories (BIO-B) scores 63 out of 100, which reads neutral, higher than 82% of Healthcare stocks and 85% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 62, technicals 66.

Among the fundamentals, Earnings Growth (Annual) at 100 and Earnings Growth (Quarterly) at 99 score highest, while PEG Ratio at 3 weighs the most against it.

On the daily chart, trend-following indicators average 64 and contrarian oscillators 20 — a split worth reading before trusting the technical total.

About Bio-Rad Laboratories

Bio-Rad Laboratories (BIO-B) makes products for life science research and clinical diagnostics. Its Life Science segment sells instruments and reagents such as Droplet Digital PCR systems, real-time PCR, electrophoresis and western blotting products, flow cytometry tools and chromatography resins to academic labs and biopharma companies. Its Clinical Diagnostics segment provides quality control products, blood typing systems, diabetes monitoring tests and infectious disease and autoimmune assays to hospital and reference laboratories. Much of its revenue comes from consumables used on installed instruments. The company also holds a large stake in Sartorius, a German life science company, and has Class A and Class B shares that differ mainly in voting rights.

Bio-Rad competes with Thermo Fisher Scientific, Qiagen, Danaher, Roche and Werfen, among others. Its edge rests on a broad installed base of instruments, a strong position in diagnostic quality controls and its digital PCR technology. Investors who follow BIO-B stock tend to watch core revenue growth, operating margins and cost-cutting progress. Demand from academic researchers and biotech companies, along with China, is closely followed. Changes in the value of the Sartorius stake, which can swing reported earnings, cost-saving programs and competition in digital PCR are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward BIO-B’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

62

Pulling it up

Holding it back

  • PEG divides the P/E ratio by the earnings growth rate.

  • Earnings estimates score evaluates analyst projections for future profitability.

  • 5-year revenue growth analyzes long-term sales trajectory and consistency.

32 weighted scorers; 7 had no data today and are left out rather than counted as zero.

Technical · daily

59

Pulling it up

  • On-Balance Volume (OBV) tracks cumulative volume flow, adding volume on up days and subtracting on down days.

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

  • Stochastic (14) places the close within its 14-day high-low range.

Holding it back

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Williams %R (28-period) places the close within the last 28 periods' high-low range.

  • Williams %R (14-period) measures where the current price sits within the recent high-low range.

65 weighted scorers.

Technical score by timeframe

ChartScoreWeight
Hourly691
Daily593
Weekly672
Monthly692
Quarterly692

Composite score, last 90 days

05010063Nov 16, 2026Nov 20, 2026Nov 16, 2026: 63Nov 18, 2026: 63Nov 19, 2026: 63Nov 20, 2026: 63
Show the daily numbers
DateComposite
Nov 20, 202663
Nov 19, 202663
Nov 18, 202663
Nov 16, 202663

Key facts

Market cap
$10.5B
Sector
Healthcare
Industry
Medical Devices
Beta
1.06
Risk grade (1–10)
—
Next earnings
—

Questions

What is BIO-B's stock rating today?

BIO-B scores 63/100 (Neutral) as of Nov 19, 2026: technical 66, fundamental 62. Scores are recomputed every night.

What does Bio-Rad Laboratories do?

Bio-Rad Laboratories (BIO-B) makes products for life science research and clinical diagnostics. Its Life Science segment sells instruments and reagents such as Droplet Digital PCR systems, real-time PCR, electrophoresis and western blotting products, flow cytometry tools and chromatography resins to academic labs and biopharma companies.

Is BIO-B stock a buy?

The score is not a buy or sell recommendation. A 63 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the BIO-B score calculated?

97 weighted scorers feed it today: 32 fundamental, scored against Healthcare ranges, and 65 technical on the daily chart, with 5 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

BIO-B stock score

HTML

<a href="https://stocksscores.com/stocks/bio-b/"><img src="https://stocksscores.com/stocks/bio-b/badge.svg" alt="BIO-B stock score" height="20"></a>

Markdown

[![BIO-B stock score](https://stocksscores.com/stocks/bio-b/badge.svg)](https://stocksscores.com/stocks/bio-b/)